Contact
Email: sjuul@uw.edu
Phone: 206.221.6814
Biography
Dr. Juul leads a translational neonatal neuroscience research program. The focus is to identify new therapeutic approaches to neonatal brain injury, determine whether they are safe and effective, and if so, bring these new treatments from the laboratory to the bedside.
Dr. Juul identified Epo and its receptor in the developing human brain, demonstrated that it is neuroprotective and safe using multiple animal models of neonatal brain injury. Bringing this work from the bench to the bedside, Dr. Juul is currently Principal Investigator of a multicenter randomized controlled trial to determine whether Epo is a safe and effective neuroprotectant for extremely preterm infants. The study, Preterm Epo Neuroprotection (PENUT) is funded by NINDS, and has enrolled 940 babies born between 24-0/7 and 26-6/7 weeks of gestation. These children are currently being followed to two years of age for detailed neurodevelopmental assessments.
Dr. Juul is also multi-PI with Dr. Yvonne Wu (UCSF) on the High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL) Trial, a randomized controlled trial of Epo neuroprotection for 500 term infants with hypoxic-ischemic encephalopathy (HIE). This multicenter trial will determine whether Epo in addition to therapeutic cooling will improve the outcome for infants with HIE.
More about Dr. Juul …
Dr. Sandra Juul
- Reflections on Neonatal Erythropoietin Neuroprotection Studies September 10, 2024
- Perinatal arterial ischemic stroke diagnosed in infants receiving therapeutic hypothermia for hypoxic-ischemic encephalopathy August 27, 2024
- Pipeline to Neonatal Clinical Transformation: The Importance of Preclinical Data August 2, 2024
- Early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy: a multicentre double-blind pilot randomised controlled trial May 10, 2024
- Genetic and Congenital Anomalies in Infants With Hypoxic-Ischemic Encephalopathy March 22, 2024
BOARD CERTIFICATION(S)
Pediatrics
Neonatal-Perinatal Medicine
MEDICAL/PROFESSIONAL SCHOOL
University of Washington School of Medicine, Seattle, WA
University of Chicago, Chicago, IL
RESIDENCY
University of Washington School of Medicine, Seattle, WA
FELLOWSHIP
Seattle Children’s Hospital, Seattle, WA
CLINICAL INTERESTS
Non-hematopoietic effects of erythropoietin (Epo), particularly its neuroprotective effects. Hematopoiesis and iron balance in preterm infants are additional areas of interest and research.
| Presentations Title | Event | Location | Date |
|---|---|---|---|
| Urine hepcidin and iron regulation in preterm infants | PAS 2018 | Toronto, ON | May 2018 |
| Examining pulmonary monocyte/macrophage populations in BPD pathogenesis | PAS 2018 | Toronto, ON | May 2018 |
| Ontogeny Of Toll-Like 3 And 4 Receptor Expression And White Matter Development In The Ferret Brain | PAS 2018 | Toronto, ON | May 2018 |
| Reticulocyte Hemoglobin Values in Preterm Infants | PAS 2018 | Toronto, ON | May 2018 |
| Lysosomal Enzyme Activities Does Not Predict Development of Necrotizing Enterocolitis | PAS 2018 | Toronto, ON | May 2018 |
| Award Name | Awarded By | Date |
|---|---|---|
| Seattle Top Doctor 2019 | Seattle Magazine | 2019 |
| Seattle Top Doctor 2018 | Seattle Met Magazine | 2018 |
| Seattles Top Doctor 2016 | Seattle Met Magazine | 2016 |
| Seattle Top Doctor 2014 | Seattle Met Magazine | 2014 |
